Immune Therapeutics Inc. (“IMUN”) was founded in September 2012 by patients who have benefited from these novel affordable, non-toxic therapies for the treatment of immune dysfunction and other chronic inflammatory disease and cancer. Our patented technology platform is based on two interrelated proven immunomodulatory drugs that activate and rebalance the Immune System.
The company has licensed from Cytocom for Emerging Markets and Animals the intellectual property surrounding Low Dose Naltrexone (“Lodonal”) and Met-Enkelphine (“MENK”) including patents, clinical data, and IRB’s and orphan drug designations so we would be able to develop the therapies for the treatment of Crohn’s Disease, MS, IBS, Fibromyalgia, Autism, HIV/AIDS and various Cancer using existing data that lowers both risk and time to market.
The purpose of our immunotherapy is to stimulate or rebalance the immune system rather than to suppress the immune system. By stimulating and rebalancing the immune system it increases production of DC cells, Macrophages, CD4+T Cells (CD4), CD8+T cells, NK cells, NKT cells, and Gammadelta T cells. And it inhibits Treg cells, to allow the body to recognize and kill cancer cells, control infection with various microbial agents, and to control the inflammation and destruction of normal tissues by autoimmune diseases
The Company's proprietary technology platform is based on two interrelated cytokine drug therapies—Low-Dose Naltrexone (Lodonal) and Methionine Enkephalin (MENK)—which work by triggering a number of receptors. One is the opioid and T Cell receptors on immune cells, which activate or balance various cells of the immune system. It also triggers the tolling receptors to shift Th1 (pro-inflammatory) to Th2 (anti-inflammatory), which is critical when dealing with autoimmune and inflammatory disease.